Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced that the Group is actively focused on employees carrying out best practices in respect of the prevention and containment of COVID-19 while ensuring continued supply of medicines to patients.
Stephen Saad, Aspen Group Chief Executive said, “As articulated by our President Cyril Ramaphosa, COVID-19 raises unprecedented challenges for both South Africa and the world. These challenges require an extraordinary response from every sector of society, not least the domestic pharmaceutical industry. These challenges have been exacerbated by the ban from India on the export of a range of pharmaceutical products and their raw materials.”
“Aspen is in discussion with the South African Government to make available, wherever feasible, its extensive South African oral solid and liquid pharmaceutical manufacturing operations for priority treatment of the South African public. This will entail adjusting some of Aspen’s production plans.”
“We echo our President’s appeal to the South African public for their assistance during this unprecedented time. Aspen has seen a spike in inquiries and demand in some of its over–the-counter pain, respiratory and colds and flu medicines. We wish to emphasise that our supply chain is currently robust and panic-buying will create unnecessary stress.”
“At this time, Aspen wishes to reassure the South African public of its commitment to them.”